摘要
人源性肿瘤组织异种移植(patient-derived tumor xenografts,PDTX)是指将患者的新鲜肿瘤组织处理后移植到免疫缺陷鼠上,依靠小鼠提供的微环境进行生长,其特点和价值不同于人源性肿瘤细胞系异种移植模型。PDTX模型保持了肿瘤细胞的分化程度、形态特征、结构特点以及分子特性。这种小鼠模型肿瘤的血运特点、基质特征、坏死状况等与人本身的肿瘤特点更为接近,这为肿瘤的生物学研究、诊断标志物的寻找和药物筛选提供了一个重要的体内模型。此外,根据移植部位的不同,PDTX模型能够体现标本来源患者肿瘤的各自特点,包括对药物反应的特异性等。因此,这种模拟人肿瘤特异性的模型对肿瘤临床前期评估、治疗和预后具有重要的转化意义,特别是对于肿瘤的个体化诊断和治疗具有不可代替的价值。
Patient-derived tumor xenografts (PDTX)which graft human tumor material into immunocompetent or immunodeficient mouse overcome the disadvantages of cell line-derived xeno-grafts.Patient-derived tumor xenografts maintain the cell differentiation and morphology,the archi-tecture,and molecular signatures of the original patient tumors.Vasculature,stroma,central necro-sis,and peripheral growth occur in tumor bearing mice in a way that is similar to that of the patient′s tumor,then there will be a higher correlation between drug response of tumor xenografts with the corresponding original tumors.But beyond that,patient-derived tumor xenograft models that are clin-ically representative of each major human cancer type would largely increase the success in identi-fying new active agents for targeting particular tumours.Therefore,these individualised models of human cancers would have an important significance for preclinical tumor assessment,treatment and prognosis and greatly facilitate selecting the best therapy for each individual patient.
出处
《转化医学杂志》
2014年第2期65-68,共4页
Translational Medicine Journal
基金
国家自然科学资金资助项目(81071736)
关键词
人源性肿瘤组织异种移植
原发肿瘤
个体化治疗
Patient-derived tumor xenografts(PDTX)
Primary tumor
Individual treatment
